沙库巴曲缬沙坦对高血压左心室肥厚的临床疗效研究

张婷婷; 葛慧娟; 庄晓赛; 任磊; 宁彬

doi:10.16766/j.cnki.issn.1674-4152.003068

沙库巴曲缬沙坦对高血压左心室肥厚的临床疗效研究

doi: 10.16766/j.cnki.issn.1674-4152.003068

阜阳市人民医院心血管内科，安徽阜阳 236000

基金项目:

安徽省卫生健康委科研项目 AHWJ2021b070

蚌埠医学院自然科学类科技项目 2020byzd354

详细信息

通讯作者:
葛慧娟，E-mail：1157840471@qq.com

中图分类号: R541.3 R972.4
计量
- 文章访问数: 363
- HTML全文浏览量: 271
- PDF下载量: 15
- 被引次数: 0
出版历程
- 收稿日期: 2022-11-28
- 网络出版日期: 2023-08-28

Clinical efficacy of sacubitril/valsartan in the treatment of hypertension with left ventricular hypertrophy research

Department of Cardiology, Fuyang People ' s Hospital, Fuyang, Anhui 236000, China

摘要

摘要: 目的探讨沙库巴曲缬沙坦对高血压合并左心室肥厚的逆转作用。方法选取2021年2—8月于阜阳市人民医院心血管内科就诊的门诊及住院的90例高血压左心室肥厚患者，其中男性56例，女性34例，按随机数字表法随机分为3组，分别为沙库巴曲缬沙坦组(A组)、贝那普利组(B组)、缬沙坦组(C组)，每组30例，随访12个月，比较3组室间隔厚度(IVST)、左室舒张末期后壁厚度(LVPWd)、左心室质量指数(LVMI)等左心室肥厚指标、左心室舒张末期内径(LVEDD)、左室射血分数(LVEF)等左室重构及功能指标、血压控制达标率等临床疗效、不良反应及并发症发生情况。结果治疗后，3组患者IVST、LVPWd、LVMI等左心室肥厚指标和LVEDD、LVEF等左室重构及功能指标均有明显改善(均P<0.05)，其中A组IVST、LVPWd、LVMI、LVEDD、LVEF指标分别为10.00(10.00, 11.00)mm、10.00(9.25, 10.75)mm、81.38(71.03, 99.34)g/m²、43.00(41.00, 47.75)mm、64.00%(60.00%，67.00%)，较其他2组改善效果显著, 变化幅度差异有统计学意义(P<0.05)。3组血压控制达标率分别为：A组86.67%、B组56.67%、C组53.33%，与B、C组比较，A组血压达标率明显增高，差异有统计学意义(均P<0.05)。3组不良反应及并发症发生率比较，差异无统计学意义(P>0.05)。结论沙库巴曲缬沙坦可逆转高血压左心室肥厚，改善心室重构及患者预后，降压效果明显，安全性良好。
- 沙库巴曲缬沙坦 /
- 高血压 /
- 左心室肥厚 /
- 贝那普利 /
- 缬沙坦
Abstract: Objective To explore the role of sacubitril/valsartan in reversing hypertension with left ventricular hypertrophy. Methods Ninety patients with hypertension and left ventricular hypertrophy who visited the Department of Cardiology of Fuyang People's Hospital from February to August 2021 were selected as the research objects, including 56 males and 34 females. They were divided into sacubitril/valsartan (A) group, benazepril (B) group and valsartan (C) group according to random numerical table, with 30 cases in each group, and followed up for 12 months. The degree of left ventricular hypertrophy index interventricular septal thickness (IVST), left ventricular posterior wall thickness in diastole (LVPWd), left ventricular mass index (LVMI), left ventricular remodeling and functional indexes such as left ventricular end diastolic diameter (LVEDD) and left ventricular ejection fraction (LVEF), the blood pressure compliance rate, clinical efficacy, occurrence of adverse reactions and complications were compared between the three groups. Results After treatment, the left ventricular hypertrophy index (IVST, LVPWd and LVMI) and the left ventricular remodeling and functional index (LVEDD and LVEF) of the three groups were significantly improved than those before treatment, all the difference was statistically significant (all P<0.05), and the IVST, LVPWd, LVMI, LVEDD, LVEF of the A group were 10.00 (10.00, 11.00) mm, 10.00 (9.25, 10.75) mm, 81.38 (71.03, 99.34) g/m², 43.00 (41.00, 47.75) mm and 64.00%(60.00%, 67.00%), which were better than the other two groups, the difference in amplitude of change was statistically significant (P<0.05). The blood pressure compliance rate were 86.67% of the group A, 56.67% of the group B, and 53.33% of the group C. The blood pressure compliance rate in Group A significantly increased, with a statistically significant difference (all P<0.05). There was no significant difference in the incidence of adverse reactions and complications during treatment among the three groups (P>0.05). Conclusion Sacubitril/valsartan can relieve the degree of left ventricular hypertrophy in the treatment of hypertension complicated with left ventricular hypertrophy, improve ventricular remodeling and patient prognosis, the effect of reducing pressure is obvious, and the safety is good.
- Sacubitril/valsartan /
- Hypertension /
- Left ventricular hypertrophy /
- Benazepril /
- Valsartan

HTML全文

表 1 3组高血压左心室肥厚患者一般临床资料比较

Table 1. Comparison of general clinical data among the three groups of hypertensive patients with left ventricular hypertrophy

组别	例数	性别[例(%)]		年龄[M(P₂₅, P₇₅), 岁]	病程[M(P₂₅, P₇₅), 年]	BMI[M(P₂₅, P₇₅)]
组别	例数	男性	女性	年龄[M(P₂₅, P₇₅), 岁]	病程[M(P₂₅, P₇₅), 年]	BMI[M(P₂₅, P₇₅)]
A组	30	19(63.33)	11(36.67)	55.00(47.00, 66.75)	9.00(4.25, 14.50)	25.75(23.32, 28.77)
B组	30	18(60.00)	12(40.00)	63.50(54.00, 70.50)	10.00(5.00, 10.00)	26.70(24.15, 29.25)
C组	30	19(63.33)	11(36.67)	61.00(56.00, 73.00)	7.50(5.00, 10.00)	25.45(23.02, 28.32)
统计量		0.095^a		4.455^b	0.822^b	1.694^b
P值		0.954		0.108	0.663	0.429

组别	例数	治疗前SBP [M(P₂₅, P₇₅), mmHg]	治疗前DBP [M(P₂₅, P₇₅), mmHg]	高脂血症 [例(%)]	糖尿病 [例(%)]	冠心病 [例(%)]
A组	30	162.50(152.00, 167.00)	90.00(82, 00, 96.75)	7(23.33)	3(10.00)	4(13.33)
B组	30	156.00(148.00, 159.50)	88.00(79.25, 96.75)	6(20.00)	4(13.33)	5(16.67)
C组	30	154.00(146.00, 164.00)	91.00(77.00, 100.00)	5(16.67)	3(10.00)	4(13.33)
统计量		5.581^b	0.106^b	0.417^a	0.225^a	0.180^a
P值		0.061	0.948	0.812	0.894	0.914
注：^a为χ²值，^b为H值。1 mmHg=0.133 kPa。

下载: 导出CSV

表 2 3组治疗前后血压变化及血压达标率比较

Table 2. Comparison of blood pressure changes before and after treatment and the rate of blood pressure reaching standard among the three groups

组别	例数	SBP[M(P₂₅, P₇₅), mmHg]		V值	P值	DBP[M(P₂₅, P₇₅), mmHg]		V值	P值	血压达标率(%)
组别	例数	治疗前	治疗后	V值	P值	治疗前	治疗后	V值	P值	血压达标率(%)
A组	30	162.50(152.00, 167.00)	120.00(116.20, 126.00)	465.000	< 0.001	90.00(82.00, 96.75)	61.5(60.00, 65.75)	465.000	< 0.001	86.67(26/30)
B组	30	156.00(148.00, 159.5)	128.00(122.00, 136.00)	465.000	< 0.001	88.00(79.25, 96.75)	70.50(65.25, 79.75)	400.500	< 0.001	56.67(17/30)^a
C组	30	154.00(146.00, 164.00)	125.00(117.80, 133.80)	465.000	< 0.001	91.00(77.00, 100.00)	70.00(65.00, 81.50)	403.000	< 0.001	53.33(16/30)^a
注：3组血压达标率比较，χ²=8.956，P=0.011；3组间血压达标率两两比较，校正检验水准为0.017，与A组比较，^aP<0.017。

下载: 导出CSV

表 3 3组治疗前后左心室肥厚指标变化比较[M(P₂₅, P₇₅)，n_i=30]

Table 3. Comparison of left ventricular hypertrophy indicators before and after treatment in the three groups [M(P₂₅, P₇₅), n_i=30]

组别	时间	IVST(mm)	LVPWd(mm)	LVMI(g/m²)	LVEDD(mm)	LVEF(%)
A组	治疗前	13.00(12.00, 14.00)	12.00(11.25, 13.00)	132.7(116.10, 143.50)	46.50(44.25, 50.75)	58.00(53.00，64.00)
	治疗后	10.00(10.00, 11.00)	10.00(9.25, 10.75)	81.38(71.03, 99.34)	43.00(41.00, 47.75)	64.00(60.00，67.00)
	V值	435.000	465.000	465.000	437.000	< 0.001
	P值	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001
B组	治疗前	12.50(12.00, 14.00)	12.00(11.00, 12.00)	121.41(102.08, 129.06)	45.00(43.25, 47.75)	60.00(56.00，65.00)
	治疗后	12.00(11.00, 13.00)	10.00(10.00, 11.00)	97.13(86.43, 114.90)	44.50(42.25, 46.00)	63.00(59.00，66.00)
	V值	406.000	406.000	465.000	348.500	53.500
	P值	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001
C组	治疗前	13.00(12.00, 14.00)	12.00(11.00, 12.00)	125.36(111.83, 134.46)	45.00(43.00, 50.00)	62.00(58.00，66.00)
	治疗后	12.00(11.00, 13.00)	11.00(10.00, 11.75)	100.99(88.82, 114.75)	44.50(42.00, 49.00)1	63.00(59.00，68.00)
	V值	465.000	351.000	464.000	364.500	62.000
	P值	< 0.001	0.001	< 0.001	0.003	0.001
	H值^a	2.529	3.714	< 0.001	1.115	4.374
	P值^a	0.282	0.156	0.251	0.573	0.112
注：^a为治疗前3组间比较的H值和P值。

下载: 导出CSV

表 4 各组治疗前后相关指标变化幅度比较[M(P₂₅, P₇₅), %]

Table 4. Comparison of the change amplitude of relevant indexes before and after treatment in each group[M(P₂₅, P₇₅), %]

组别	例数	SBP降幅	DBP降幅	IVST降幅	LVPWd降幅	LVMI降幅	LVEDD降幅	LVEF增幅
A组	30	32.50(28.11, 37.08)	35.68(16.74, 53.31)	27.27(20.00, 33.33)	22.22(20.00, 29.32)	52.76(43.69, 65.59)	6.68(4.71, 9.25)	9.92(4.69, 13.09)
B组	30	21.31(13.91, 26.51)	21.78(9.30, 38.17)	8.71(7.69, 10.09)	10.00(9.09, 10.00)	18.05(16.54, 24.08)	2.35(2.07, 3.32)	3.36(2.74, 5.09)
C组	30	24.80(17.03, 32.79)	22.71(9.90, 37.78)	9.09(8.33, 14.05)	9.55(8.52, 14.32)	17.89(14.91, 26.68)	2.33(1.98, 2.62)	1.87(1.38, 3.43)
H值^a		16.273	6.213	29.696	30.964	44.007	26.735	22.46
P值^a		< 0.001	0.045	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001
Z值^b		1 873.500	1 648.000	2 053.000	2 023.000	2 113.000	1 974.000	2 004.500
P值^b		< 0.001	0.014	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001
注：^a为3组间整体比较的H值和P值；^b为3组间趋势性比较的Z值和P值。

下载: 导出CSV

参考文献(21)

[1]	YILDIZ M, OKTAY A A, STEWART M H, et al. Left ventricular hypertrophy and hypertension[J]. Prog Cardiovasc Dis, 2020, 63(1): 10-21. doi: 10.1016/j.pcad.2019.11.009
[2]	诸国华, 孙希鹏, 唐桦, 等. 初发轻度高血压患者内皮功能与左心室肥厚的相关性研究[J]. 首都医科大学学报, 2019, 40(3): 369-373. doi: 10.3969/j.issn.1006-7795.2019.03.009 ZHU G H, SUN X P, TANG H, et al. Correlation between endothelial function and left ventricular hypertrophy in patients with untreated mild hypertension[J]. Journal of Capital Medical University, 2019, 40(3): 369-373. doi: 10.3969/j.issn.1006-7795.2019.03.009
[3]	王杏芬, 高永红, 孙萌. 高血压病患者APN、MMP-9、Ang Ⅱ、ET-1水平与左心室肥厚的相关性研究[J]. 河北医药, 2021, 43(7): 1037-1039, 1043. doi: 10.3969/j.issn.1002-7386.2021.07.017 WANG X F, GAO Y H, SUN M. Correlation between adiponectin, MMP-9, AngⅡ, ET-1 and left ventricular hypertrophy in patients with hypertension[J]. Hebei Medical Journal, 2021, 43(7): 1037-1039, 1043. doi: 10.3969/j.issn.1002-7386.2021.07.017
[4]	冯颖青. 高血压合并左心室肥厚: what's news?[J]. 中华高血压杂志, 2017, 25(7): 616-618. FENG Y Q. Hypertension with left ventricular hypertrophy: what's the news?[J]. Chinese Journal of Hypertension, 2017, 25(7): 616-618.
[5]	中国高血压防治指南修订委员会. 中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志, 2019, 24(1): 24-56. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGGZ201904005.htm Revision committee of guidelines for the prevention and treatment of hypertension in China. Guidelines for the prevention and treatment of hypertension in China (2018 revision)[J]. Prevention and Treatment of Cardio-Cerebral-Vascular Disease, 2019, 24(1): 24-56. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGGZ201904005.htm
[6]	中华医学会心血管病学分会高血压学组. 强化血压控制中国专家建议[J]. 中华高血压杂志, 2022, 30(2): 113-117. https://www.cnki.com.cn/Article/CJFDTOTAL-JSWB202208041.htm Hypertension group of chinese society of cardiology. Chinese expert advice on strengthening blood pressure control[J]. Chinese Journal of Hypertension, 2022, 30(2): 113-117. https://www.cnki.com.cn/Article/CJFDTOTAL-JSWB202208041.htm
[7]	孙宁玲, Jaw-Wen Chen, 王继光, 等. 亚洲高血压合并左心室肥厚诊治专家共识[J]. 中华高血压杂志, 2016, 24(7): 619-627. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGGZ201607008.htm SUN N L, JAW-WEN CHEN, WANG J G, et al. Asian expert consensus on the diagnosis and treatment of hypertension with left ventricular hypertrophy[J]. Chinese Journal of Hypertension, 2016, 24(7): 619-627. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGGZ201607008.htm
[8]	束长城, 魏万林. 高血压左心室肥厚的形成机制研究进展[J]. 中国循证心血管医学杂志, 2018, 10(6): 760-762. doi: 10.3969/j.issn.1674-4055.2018.06.35 SU C C, WEI W L. Research progress in formation mechanism of hypertensive left ventricular hypertrophy[J]. Chinese Journal of Evidence-Based Cardiovascular Medicine, 2018, 10(6): 760-762. doi: 10.3969/j.issn.1674-4055.2018.06.35
[9]	韩萌, 习玲, 陈李娟. 老年人原发性高血压左心室肥厚致病机制的研究进展[J]. 中西医结合心脑血管病杂志, 2021, 19(18): 3127-3132. doi: 10.12102/j.issn.1672-1349.2021.18.012 HAN M, XI L, CHEN L J. Research progress on the pathogenesis of left ventricular hypertrophy in elderly patients with essential hypertension[J]. Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease, 2021, 19(18): 3127-3132. doi: 10.12102/j.issn.1672-1349.2021.18.012
[10]	朱林, 洪梅. 沙库巴曲/缬沙坦在心血管疾病治疗中的研究进展[J]. 中华老年多器官疾病杂志, 2020, 19(5): 384-387. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLQG202005019.htm ZHU L, HONG M. Research progress on sacubitril-valsartan in treatment of cardiovascular diseases[J]. Chinese Journal of Multiple Organ Diseases in the Elderly, 2020, 19(5): 384-387. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLQG202005019.htm
[11]	VARDENY O, CLAGGETT B, KACHADOURIAN J, et al. Incidence, predictors, and outcomes associated with hypotensive episodes among heart failure patients receiving sacubitril/valsartan or enalapril: the PARADIGM-HF Trial (prospective comparison of angiotensin receptor neprilysin inhibitor with angiotensin-converting enzyme inhibitor to determine impact on global mortality and morbidity in heart failure)[J]. Circ Heart Fail, 2018, 11(4): e004745. DOI: 10.1161/CIRCHEARTFAILURE.117.004745.
[12]	中国医疗保健国际交流促进会高血压分会, 中国医师协会心血管分会, 中国高血压联盟, 等. 沙库巴曲缬沙坦在高血压患者临床应用的中国专家建议[J]. 中华高血压杂志, 2021, 29(2): 108-114. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGGZ202102006.htm Hypertension Branch of Chinese International Exchange and Promotion Association for Medical and Healthcare, Cardiovascular Branch of Chinese Medical Doctor Association, Chinese Hypertension Alliance, et al. Chinese expert recommendations on the clinical application of sacubitril/valsartan in patients with hypertension[J]. Chinese Journal of Hypertension, 2021, 29(2): 108-114. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGGZ202102006.htm
[13]	WANG T D, TAN R S, LEE H Y, et al. Effects of sacubitril/valsartan (LCZ696) on natriuresis, diuresis, blood pressures, and NT-proBNP in salt-sensitive hypertension[J]. Hypertension, 2017, 69(1): 32-41.
[14]	CHEUNG D G, AIZENBERG D, GORBUNOV V, et al. Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: a randomized, double-blind, 8-week study[J]. J Clinical Hypertension (Greenwich), 2018, 20(1): 150-158.
[15]	CHUA S K, LAI W T, CHEN L C, et al. The antihypertensive effects and safety of LCZ696 in patients with hypertension: a systemic review and meta-analysis of randomized controlled trials[J]. J Clin Med, 2021, 10(13): 2824. DOI: 10.3390/jcm10132824.
[16]	SUPASYNDH O, WANG J, HAFEEZ K, et al. Efficacy and safety of sacubitril/valsartan(LCZ696) compared with olmesartan in elderly asian patients (≥ 65 years) with systolic hypertension[J]. Am J Hypertens, 2017, 30(12): 1163-1169.
[17]	DESAI A S, SOLOMON S D, SHAH A M, et al. Effect of sacubitril-valsartan vs. enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial[J]. JAMA, 2019, 322(11): 1077-1084.
[18]	MC CAUSLAND F R, LEFKOWITZ M P, CLAGGETT B, et al. Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction[J]. Circulation, 2020, 142(13): 1236-1245.
[19]	李晓明, 商睿, 郝盼盼. 苯磺酸氨氯地平与缬沙坦逆转左心室肥厚疗效的对比研究[J]. 中华全科医学, 2016, 14(8): 1330-1331, 1424. doi: 10.16766/j.cnki.issn.1674-4152.2016.08.028 LI X M, SHANG R, HAO P P. Comparison of benzene sulfonic acid amlodipine and Valsartan in reversion of left ventricularhypertrophy in patients with essential hypertension[J]. Chinese Journal of General Practice, 2016, 14(8): 1330-1331, 1424. doi: 10.16766/j.cnki.issn.1674-4152.2016.08.028
[20]	崔启, 袁晓鹏, 张静. 沙库巴曲缬沙坦在高血压患者治疗中应用研究进展[J]. 中华实用诊断与治疗杂志, 2022, 36(8): 859-861. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZD202208025.htm CUI Q, YUAN X P, ZHANG J. Application of sacubitril/valsartan in the treatment of hypertension[J]. Journal of Chinese Practical Diagnosis and Therapy, 2022, 36(8): 859-861. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZD202208025.htm
[21]	黎冉, 谢丽娟, 焦长青, 等. 沙库巴曲缬沙坦对不同射血分数心力衰竭患者的疗效及预后[J]. 中华全科医学, 2021, 19(1): 10-13. doi: 10.16766/j.cnki.issn.1674-4152.001716 LI R, XIE L J, JIAO C q, et al. Clinical effect and prognosis of sacubitril-valsartan in treating heart failure patients with different ejection fraction[J]. Chinese Journal of General Practice, 2021, 19(1): 10-13. doi: 10.16766/j.cnki.issn.1674-4152.001716